羟乙膦酸钠对实验性高钙尿症的防治作用及其机制

目的：观察骨吸收抑制剂羟乙膦酸钠对实验性高钙尿症的防治作用，并其可能机制。方法：建立大鼠实验性高钙尿症模型，观察羟乙膦酸钠治疗后２周和４周的尿钙，Ｃａ＾２＋／Ｃｒ，ＮＡＧ／Ｃｒ，以及肾和十二揸肠Ｃａ＾２＋－ＡＴＰ酶（钙泵）的变化。结果：２周时尿钙，Ｃａ＾２＋／Ｃｒ，血ＡＬＰ量有所升高，但４周时尿钙，Ｃａ＾２Ｃｒ，ＮＡＧ／Ｃｒ及血ＡＬＰ均显著下降（Ｐ〈０．０１），２４小时尿一量与尿ＮＡＧ／Ｃｒ值呈正

Therapeutic effects of etidronate on experimental hypercalciuria and its mechanism

Objective:To observe the therapeutic effects of etidronate (a drug of bone absorption inhibitors) on experimental hypercalciuria and clarify its pharmacological mechanism. Methods:The urine calcium creatinine ratios(Ca 2+ /Cr),24 hours quantitative urinary calcium (UCa 2+ ), N acetyl beta D glucosaminidase creatinine ratios(NAG/Cr) and activity of Ca 2+ ATPase on both kidney and duodenum were measured after 2 and 4 weeks treatment of etidronate in rat models of hypercalciuria established by injection of vitamin D 3. Results: Ca 2+ /Cr, UCa 2+ , NAG/Cr were significantly decreased in rats treated with etidronate at 4th week as compared with rats injected with vitamin D 3, while activity of Ca 2+ ATPase on target tissues were not changed. A marked positive relationship was found between UCa 2+ and NAG/Cr. Conclusion: Etidronate displays a remarkable anticalciuric actions independent of changes of Ca 2+ ATPase on target tissues, suggesting that bone absorption inhibitors could be prescribed into idiopathic hypercalciuria therapy.